Every material Form 8-K Biofrontera Inc. has filed with the SEC since May 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The FDA approved Biofrontera's supplemental New Drug Application for Ameluz with the BF-RhodoLED lamp for superficial basal cell carcinoma in adults. The company says this makes Ameluz the first and only photodynamic therapy approved by the FDA for a skin cancer, and that it expands the addressable market. The filing gives no revenue, sales or financial impact figures.
FDA approval announced September 14, 2026 for Ameluz with BF-RhodoLED lamp for superficial basal cell carcinoma in adults
Phase 3 trial in 187 adults: 66% (95 of 145) of Ameluz PDT subjects achieved the primary endpoint versus 5% (2 of 42) on placebo-PDT
Company plans an official launch of the new indication late in Q4 2026 through Q1 2027, using its existing commercial organization and lamp base
Biofrontera reported second-quarter 2026 net product revenue of $12.0 million, up 32.9% from a year earlier, and a net loss of $0.6 million, compared with $5.3 million in the prior-year quarter. The company attributed its gross margin rise to 80% from 71% mainly to a lower Ameluz cost structure following its October 2025 strategic transaction with Biofrontera AG. The filing also notes an ITC exclusion order on its RhodoLED XL lamp, effective July 7, 2026, and cash of $4.7 million as of June 30, 2026.
Net product revenue was $12.0 million for Q2 2026, up $3.0 million, or 32.9%, from $9.0 million.
Gross margin was 80% versus 71%; net loss was $0.6 million, or $(0.05) per share, versus $5.3 million, or $(0.57) per share.
An ITC exclusion order on the RhodoLED XL lamp took effect July 7, 2026; the company says it is pursuing a remediation plan for a modified lamp.
Cash and cash equivalents were $4.7 million at June 30, 2026; total stockholders' equity was $6.0 million, down from $10.5 million at December 31, 2025.
Biofrontera reported first quarter 2026 revenue of $10.1 million, up about 17% from a year earlier, with gross margin near 80% after a restructured earnout following its October 2025 strategic transaction with Biofrontera AG. The net loss widened to $4.8 million from $4.2 million, though the loss per share improved to $0.41 from $0.47 on a higher share count, so shareholders get mixed signals on profitability.
Revenue was $10.1 million versus $8.6 million, driven by about 16% growth in Ameluz units sold and a price increase in Q4 2025.
Gross margin was about 80% versus about 62%; SG&A rose to $11.0 million from $8.7 million.
Net loss was $4.8 million, or $0.41 per share, versus $4.2 million, or $0.47 per share; Adjusted EBITDA improved to $(3.6) million from $(4.4) million.
Cash and cash equivalents were $6.3 million at March 31, 2026, with $70 thousand used in operations in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Biofrontera Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →